A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic HCV for Use in the Peri-Operative Liver Transplantation Setting

Investigator: Norah A. Terrault, MD
Sponsor: Gilead Sciences, Inc.

Location(s): United States


This study will evaluate the safety, tolerability, antiviral efficacy, and pharmacokinetics of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 4 weeks in adults with genotype 1 or 4 hepatitis C virus (HCV) infection who are undergoing primary liver transplantation.